Table 2 Results from selected non-original articles
Author, year | Country | Type of publication | Aim of the study | BUP indication + dose | Main findings related to BUP | Safety considerations/side effects | Limitations |
|---|---|---|---|---|---|---|---|
Agüera-Ortiz, 2021 [43] | Europe (Spain) | Consensus of experts | To assess consensus of exerts (in Psychiatry, Neurology, and Geriatrics) about diagnosis and treatment of depression in PD. | Depression, dose not reported. | Experts agreed BUP is an efficacious pharmacological option for depression in PD. | Experts agreed BUP is well-tolerated, especially regarding the absence or a minimal increase in motor symptoms. | Consensus of experts using Delphi methodology and limited number of experts (n = 37). |
Mills, 2018 [44] | North America (the USA) | Systematic review and meta-analysis | To review and analyze results of RCTs about efficacy and tolerability of different antidepressants in PD (20 studies, 5 included in meta-analyses). | Depression, dose not reported. | One study on BUP is listed among treatment options for depression in PD, but data on BUP were not further discussed or included in meta-analyses. | Not reported. | Limited data on BUP. |
Paumier, 2010 [45] | North America (the USA) | Meta-analysis | To investigate the effect of different antidepressants (including BUP) on PD progression (data from 6 RCTs, including 2064 subjects with PD prescribed antidepressants or placebo) | Not reported. | Antidepressant- treated subjects showed a lower probability of requiring dopaminergic therapy than those not taking antidepressants (HR = 0.6, p < 0.001); effect not specific to a particular class of antidepressant. Mean change in UPDRS scores was significantly lower in subjects treated with atypical antidepressants (including BUP) than those not taking antidepressants (p < 0.05). | Not reported. | Only abstract available (poster conference). |
Pena, 2018 [46] | Europe (Spain) | Clinical guidelines | To establish a series of clinical recommendations on the use of antidepressants in patients with PD, based on a systematic review of the literature. | Depression,150–300 mg/day. | Clinicians should consider BUP to treat apathy in pts. with PD (class IV: other studies, including consensus or expert opinion; recommendation U: inadequate or conflicting data). | Not reported. | Only one database (Medline) was searched during the review process. |
Weintraub, 2005 [47] | North America (the USA) | Review and meta-analysis | To review and analyze results about antidepressant effect in pts. with PD (27 studies, 11 included in meta-analysis, data from 772 pts. with PD and comorbid depressive symptoms/disorder). | Depression, dose not reported. | One study on BUP is listed among treatment options for depression in PD, but data on BUP was not further discussed or included in meta-analyses. | Not reported. | Limited data on BUP. |